The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Fexeric ferric citrate coordination complex Additional monitoring | Akebia Europe Limited | Hyperphosphatemia; Renal Dialysis | 🇪🇺 EU 2015-09-23 | Order → |
| Praluent alirocumab | Sanofi Winthrop Industrie | Dyslipidemias | 🇪🇺 EU 2015-09-23 | Order → |
| Pemetrexed Sandoz pemetrexed Generic | Sandoz GmbH | Carcinoma, Non-Small-Cell Lung; Mesothelioma | 🇪🇺 EU 2015-09-18 | Order → |
| Zalviso sufentanil | FGK Representative Service GmbH | Pain, Postoperative | 🇪🇺 EU 2015-09-18 | Order → |
| Zerbaxa ceftolozane;tazobactam | Merck Sharp & Dohme B.V. | Bacterial Infections | 🇪🇺 EU 2015-09-18 | Order → |
| Intuniv guanfacine | Takeda Pharmaceuticals International AG Ireland | Attention Deficit Disorder with Hyperactivity | 🇪🇺 EU 2015-09-17 | Order → |
| Pemetrexed Lilly pemetrexed Generic | Eli Lilly Netherlands | Carcinoma, Non-Small-Cell Lung; Mesothelioma | 🇪🇺 EU 2015-09-14 | Order → |
| Ivabradine Anpharm ivabradine | "Anpharm" Przedsiębiorstwo Farmaceutyczne S.A. | Angina Pectoris; Heart Failure | 🇪🇺 EU 2015-09-08 | Order → |
| Raxone idebenone Exceptional circumstancesAdditional monitoring | Chiesi Farmaceutici S.p.A | Optic Atrophy, Hereditary, Leber | 🇪🇺 EU 2015-09-08 | Order → |
| Farydak panobinostat | pharmaand GmbH | Multiple Myeloma | 🇪🇺 EU 2015-08-28 | Order → |
| Kanuma sebelipase alfa OrphanAccelerated assessmentAdditional monitoring | Alexion Europe SAS | Lipid Metabolism, Inborn Errors | 🇪🇺 EU 2015-08-28 | Order → |
| Pregabalin Accord pregabalin Generic | Accord Healthcare S.L.U. | Anxiety Disorders; Epilepsy | 🇪🇺 EU 2015-08-28 | Order → |
| Strensiq asfotase alfa OrphanExceptional circumstancesAdditional monitoring | Alexion Europe SAS | Hypophosphatasia | 🇪🇺 EU 2015-08-28 | Order → |
| Taxespira (previously Docetaxel Hospira UK Limited ) docetaxel Generic | Hospira UK Limited | Stomach Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Head and Neck Neoplasms; Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU 2015-08-28 | Order → |
| Aripiprazole Sandoz aripiprazole Generic | Sandoz GmbH | Schizophrenia; Bipolar Disorder | 🇪🇺 EU 2015-08-20 | Order → |
| Duloxetine Zentiva duloxetine Generic | Zentiva k.s. | Neuralgia; Depressive Disorder, Major; Anxiety Disorders; Diabetes Mellitus | 🇪🇺 EU 2015-08-20 | Order → |
| Respreeza alpha1-proteinase inhibitor (human) | CSL Behring GmbH | Genetic Diseases, Inborn; Lung Diseases | 🇪🇺 EU 2015-08-20 | Order → |
| Odomzo sonidegib | Sun Pharmaceutical Industries Europe B.V. | Carcinoma, Basal Cell | 🇪🇺 EU 2015-08-14 | Order → |
| Unituxin dinutuximab | United Therapeutics Europe Ltd | Neuroblastoma | 🇪🇺 EU 2015-08-14 | Order → |
| Omidria phenylephrine;ketorolac | Rayner Surgical (Ireland) Limited | Lens Implantation, Intraocular; Pain, Postoperative | 🇪🇺 EU 2015-07-28 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.